vices in many countries. Increasing age is a wellknown risk factor for venous thromboembolism occurring in both medical and surgical patients (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Elderly patients frequently have multiple risk factors for venous thromboembolism (7) (8) (9) , particularly congestive heart failure, chronic obstructive pulmonary disease, cancer, and stroke. Randomized clinical trials have demonstrated that unfractionated heparin and LMWH are effective in preventing venous thromboembolism in high-risk medical patients (6) (7) (8) (9) (10) (11) (12) (13) , but prophylaxis is frequently omitted in this patient population (14) . Fortunately, prophylaxis is more commonly prescribed for patients undergoing high-risk surgical procedures such as joint arthroplasty, hip fracture, or cancer surgery, and clinical trials in patients undergoing general surgical procedures have demonstrated that low-dose heparin significantly reduced the incidence of fatal pulmonary embolism when compared with placebo (10) .
Treatment of Venous Thromboembolism
Although newer antithrombotic agents are currently under intense investigation for the treatment of venous thromboembolism, current therapy consists of initial unfractionated heparin followed by either continuous intravenous infusion or subcutaneous LMWH once daily with concurrent warfarin therapy, the latter continued anywhere from 3 months to indefinitely (15, 16) . The main risk associated with anticoagulant therapy is hemorrhage, which can be associated with significant morbidity or mortality. Frail elderly patients are at higher risk for bleeding on anticoagulants. For this reason anticoagulant therapy may be withheld or discontinued earlier than planned in many elderly patients who may have firm indications for anticoagulant therapy. This has been particularly true in the use of oral anticoagulant therapy in patients with valvular or non-valvular atrial fibrillation.
Bleeding Risk with Unfractionated Heparin
For the treatment of venous thromboembolism, unfractionated heparin is given by continuous intravenous infusion and controlled by measurement of the activated partial thromboplastin time (aPTT) to provide a therapeutic range of 0.35 to 0.70 anti-Xa activity when measured with the chromogenic assay (16) . The use of a heparin nomogram ensures that the majority of patients are maintained within these narrow limits (17, 18) . Failure to achieve therapeutic levels of heparin with respect to the aPTT or the factor Xa levels within the first 24 to 48 hours has been associated with an increased incidence of recurrent thromboembolism during follow-up (17). It has proven more difficult to associate increased bleeding risk with either aPTT or factor Xa measurements (19) and evidence from clinical trials indicate that major bleeding is more closely associated with underlying medical conditions rather than the level of aPTT (17). Age and renal failure, as well as female gender have been identified as risk factors for bleeding on heparin (20-23).
In addition to a higher incidence of renal insufficiency, elderly patients frequently have comorbid conditions such as cancer, diabetes mellitus, hypertension, congestive heart failure, and liver disease, which predispose to bleeding on both heparin and warfarin (7) (8) (9) . The concomitant use of aspirin has been identified as a risk factor for bleeding (24, 25) . The use of thrombolysis and more potent platelet function inhibitors is associated with an even higher risk of bleeding (26,27). The use of unfractionated heparin for the treatment of venous thromboembolism in elderly patients requires careful monitoring with discontinuation of the intravenous infusion or administration of protamine sulphate as needed when bleeding occurs (15) .
Bleeding and Low-Molecular-Weight Heparin Therapy
The LMWHs have been available for the prevention and treatment of venous thromboembolism and the management of acute coronary syndromes for a number of years (3). The LMWHs have the advantage that they can be given by once-or twice-daily subcutaneous injection without laboratory monitoring (15) . Other possible advantages include decreased incidence of osteoporosis and heparin-induced thrombocytopenia (3) . Studies have shown that the LMWHs inhibit platelet-bound factor Xa (28) are resistant to inhibition by platelet factor IV (29), and have decreased effect on platelet function (30) and vascular permeability (31), suggesting that there may be fewer hemorrhagic effects at comparable antithrombotic doses (32).
Data from clinical trials indicate that the bleeding risk for LMWH is either comparable to or less than that seen with unfractionated heparin. Individual clinical trials in general surgery using LMWH for the prevention of venous thromboembolism have been associated with decreased bleeding when compared with heparin in terms of the incidence of wound hematoma, severe bleeding, and the number of patients requiring re-operation for bleeding (33). However, metaanalyses of multiple prophylaxis trials demonstrate little or no difference in the incidence of major bleeding (34). Similarly, in one doubleblind randomized clinical trial for the treatment of proximal deep vein thrombosis, the incidence of major bleeding with LMWH was significantly less than that of the unfractionated heparin (35), but meta-analyses of multiple treatment trials have depicted little or no difference (36). The conclusion from these studies is that the incidence of bleeding with prophylactic or therapeutic doses of LMWH is comparable to that with unfractionated heparin for similar or improved efficacy.
Bleeding and Warfarin Therapy
The major side effect of oral anticoagulant therapy is bleeding. Bleeding that occurs during well-controlled oral anticoagulant therapy is usually due to surgery or other forms of trauma or to local lesions such as peptic ulcer or carcinoma (19). Spontaneous bleeding may occur if warfarin is given in an excessive dose resulting in a marked prolongation of the INR and this bleeding may be severe or even life-threatening (37-40). The risk of bleeding may be substantially reduced by carefully adjusting the warfarin dose to maintain a therapeutic INR range (usually 2.0 to 3.0). Management in anticoagulant management clinics or the use of point-of-care INR testing has been shown to be more effective than routine management in maintaining patients in their desired therapeutic range (41). Although a recent study demonstrated that warfarin treatment to a targeted INR of 1.5 to 2.0 was more effective than placebo (42), another study comparing the efficacy and safety of warfarin with an INR of 2.0 to 3.0 (43) with 1.5 to 2.0 demonstrated superior efficacy with no added risk of bleeding for the INR range of 2.0 to 3.0. Therefore, there is no advantage to using warfarin in a lower dose to achieve an INR of 1.5 to 2.0 in patients who require ongoing oral anticoagulant therapy.
The use of oral anticoagulant therapy in elderly subjects presents certain unique problems (41). Warfarin has a prolonged half life that is dependent on normal hepatic function; hepatic clearance decreases with advancing age, so that older patients require significantly lower doses of warfarin (41). This requires careful monitoring and selection of a lower initiating dose of warfarin. In addition to age, there are other fac-tors associated with a lower steady-state warfarin dose requirement (41). These factors include lower body weight and mutations of the cytochrome P450 enzyme (45). In addition, numerous comorbid conditions that are common in elderly subjects influence oral anticoagulant control, such as a history of gastrointestinal (GI) bleeding, hypertension, cerebral vascular disease, congestive heart failure, renal insufficiency, and cancer (37-40).
Numerous attempts have been made to estimate bleeding risks for patients being treated with oral anticoagulants, one of which is age greater than 65 (37-41). In a large administrative database, White and colleagues analyzed the risk factors for rehospitalization for bleeding among patients initially hospitalized for venous thromboembolism (41). The rate of bleeding was highest during the first month of treatment then fell to a stable rate over the next 2 months. As in previous studies, risk factors for major bleeding requiring intervention included age 65 or older, female gender, previous GI bleeding, alcoholism, chronic renal failure, and cancer (41).
There is hope that drugs such as the specific anti-thrombin or anti-factor Xa agents, which can be taken orally in a fixed dose and do not require regular laboratory monitoring for efficacy, may be useful alternatives to warfarin in elderly patients with venous thromboembolism.
Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism
For the treatment of established venous thromboembolism, the LMWHs given by subcutaneous injection have a number of advantages over continuous intravenous unfractionated heparin; they can be given once or twice daily by subcutaneous injection, and the antithrombotic response to LMWH is highly correlated with body weight, permitting administration of a fixed dose without laboratory monitoring. This has enabled the out-of-hospital treatment of a large number of patients with venous thromboembolism. In a number of early clinical trials, LMWH given by subcutaneous or intravenous injections was compared with continuous intravenous unfractionated heparin (46-50). In these clinical trials, the primary endpoint was the change in the size of the thrombus on repeat venography at 7 to 10 days. These studies demonstrated that LMWH was at least as effective as unfractionated heparin in increasing the resolution and preventing extension of the thrombus (46-50).
Subcutaneous unmonitored LMWH has been compared with continuous intravenous unfractionated heparin in a number of clinical trials for the treatment of proximal venous thrombosis using long-term follow-up as an outcome measure (51-54). These studies have shown that LMWH is at least as effective and safe as unfractionated heparin in the treatment of proximal venous thrombosis (51-54). Pooling the most methodologically sound studies indicated a significant advantage for LMWH in the reduction of major bleeding and all-cause mortality (36). Recent studies have shown that a fixed dose of LMWH unrelated to body weight is as effective and safe as intravenous unfractionated heparin given in the hospital (55). Two clinical trials showed that LMWH was as effective and safe as intravenous unfractionated heparin for the treatment of patients presenting with pulmonary embolism (56-58). Three studies have indicated that LMWH given predominantly out-of-hospital was as effective and safe as intravenous unfractionated heparin given in the hospital (59-61). Economic analysis of treatment with LMWH versus intravenous heparin demonstrates that LMWH was cost effective for treatment in the hospital as well as out-of-hospital (62) .
LMWH has been compared with warfarin therapy for the long-term treatment of symptomatic venous thromboembolism (63, 64) . These studies were not comparable in terms of dosage and duration of LMWH. It was concluded that review of the data did not provide conclusive evidence on whether LMWH treatment was as effective as warfarin therapy in the prevention of recurrent symptomatic venous thromboembolism after an initial episode of deep vein thrombosis (64) . There was less bleeding with LMWH with equal or superior efficacy, particularly in patients with cancer when compared with warfarin (64) .
In a recent study, patients with cancer and venous thromboembolism were treated with therapeutic doses of LMWH (dalteparin) for 1 month followed by two thirds of the therapeutic dose for another 5 months and compared with initial LMWH followed by warfarin for a total of 6 months (65) . There was a significant decrease in the incidence of recurrent venous thromboembolism with comparable bleeding and mortality rates. In another study, the LMWH was given in therapeutic doses for 3 months and compared with initial LMWH followed by warfarin for 3 months in patients with proximal deep vein thrombosis who were stratified for the presence of cancer (66) . The incidence of recurrent venous thromboembolism was comparable in the two groups in the overall study but in the patients with cancer there was a significant decrease in the incidence of recurrent venous thromboembolism. These results are supported by a smaller study comparing long-term LMWH (enoxaparin) with LMWH followed by warfarin for 3 months in patients with venous thromboembolism and cancer, although the incidence of recurrent venous thromboembolism and bleeding did not differ significantly (67) . All of these studies indicate that the long-term use of LMWH is an alternative to the use of oral anticoagulant therapy, particularly in patients with cancer and venous thromboembolism (65) (66) (67) .
Special Considerations for the Use of Low-Molecular-Weight Heparin

Elderly Patients with Renal Insufficiency
The various LMWHs have different chemical and pharmacologic properties including the route of excretion. Most of the LMWHs are primarily excreted through the kidney, either following desulphation in the liver or in the unchanged form (15) . There is a variable amount of metabolism in the reticuloendothelial system including the liver. This factor helps explain the different effects of renal insufficiency on the peak and trough levels of factor Xa after the injection of prophylactic or therapeutic doses of LMWH (15) . Although monitoring anti-factor Xa levels in conjunction with LMWH therapy has been shown to be of little relevance to recurrent thrombosis or bleeding and it is not recommended for routine use, monitoring anti-factor Xa levels has been useful to detect accumulation of the drug in patients with impaired renal function (68) (69) (70) (71) . There is evidence from clinical trials that the anti-factor Xa activity of enoxaparin (72) (73) (74) (75) (76) (77) and nadroparin (78) increases in patients with impaired with renal function, particularly with a creatinine clearance less than 30 mL/min. However, the correlation of creatinine clearance with this anti-factor Xa activity and with bleeding tendency has been inconsistent (73) (74) (75) (76) (77) . Algorithms for decreasing prophylactic and therapeutic doses of enoxaparin with increasing degrees of renal insufficiency have been recommended (74, 75) . Studies with the LMWH tinzaparin have shown less evidence of accumulation of the drug in patients with creatinine clearance as low as 20 mL/min (79, 80) . This may relate to the fact that tinzaparin has a higher molecular weight and a greater proportion of the drug is metabolized in the reticuloendothelial system as compared with some of the other LMWHs (82) . The LMWHs should be used with caution in patients with severe renal insufficiency. In such patients periodic measurement of anti-factor Xa levels may be justified. As an alternative, unfractionated heparin by continuous intravenous infusion may be used.
Obesity
Although obesity is not usually a problem in elderly patients there has been uncertainty regarding the need to administer a lower dose of LMWH in patients who are overweight and particularly those who are morbidly obese as opposed to a fixed dose per kilogram body weight. The maximum dosage of dalteparin sodium for the treatment of DVT and for patients with acute coronary syndromes is 18,000 U/day when oncedaily dosing is used. The regulatory agencies have applied this recommendation to the other LMWHs as well. The rationale for capping the dose is based on pharmacokinetic data suggesting that dalteparin distributes only in the plasma volume so that dosing should not be weight based in obesity (83) . However, one study indicated that the volume of distribution and clearance of dalteparin did not differ significantly from those values in patients in normal weight, suggesting that doses of dalteparin in obese patients should be based on total body weight or adjusted body weight but not on lean body weight (85) . More recent studies with dalteparin, tinzaparin, and enoxaparin in patients with varying degrees of obesity indicate that anti-factor Xa levels are not increased in comparison with patients of normal or ideal body weight when weight-adjusted dosages of LMWH are administered (86) (87) (88) (89) (90) (91) (92) (93) . Data from these studies indicate that there is no evidence for capping the maximal fixed dose of these drugs in patients who are overweight (86) (87) (88) (89) (90) (91) (92) (93) .
Heparin-Induced Thrombocytopenia and Thrombosis
Heparin-induced thrombocytopenia with or without venous or arterial thrombosis represents a serious complication of heparin treatment. The actual incidence of heparin-induced thrombosis (HIT) in patients receiving either unfractionated heparin or LMWH is uncertain (93) (94) (95) (96) (97) (98) (99) . In a prospective cohort study of patients receiving subcutaneous unfractionated heparin for prophylaxis or treatment of venous thromboembolism, an attempt was made to determine the incidence of confirmed HIT (94) . HIT demonstrated by a positive HIT assay or unexplained thrombocytopenia occurring after 5 days of heparin and normalization within 10 days after heparin was discontinued was found in five patients (0.8%). Of note, three of the five patients experienced one or more HIT-related thrombotic events, two of which were fatal. Estimates of the incidence of HIT varies with the route of administration and the source of the heparin (i.e., bovine versus porcine) (95) . Review of the pooled analysis of prospective studies evaluating the incidence of HIT revealed an estimated incidence with the use of intravenous porcine or bovine heparin of 1.1% and 2.9%, respectively, whereas no cases were detected with the use of subcutaneous heparin (95) . However, in the study by Warkentin in patients receiving either LMWH or unfractionated heparin for the prevention of venous thrombosis following total hip replacement, HIT occurred in nine of 332 patients receiving unfractionated heparin compared with none of the 333 patients who received LMWH (2.7% vs 0%, p=0.001) (96) . Of note, eight of the nine patients with HIT had one or more thrombotic events compared with 117 of the 656 without HIT (89.9% versus 17.8%, p < 0.001) (96) .
Osteoporosis
Both heparin and LMWH can cause osteoporosis. This has been a particular problem for pregnant patients who require heparin prophylaxis or treatment throughout pregnancy (100) (101) (102) . In a study comparing the use of unfractionated heparin with LMWH for patients with venous thromboembolism and contraindications to warfarin in an older population (mean age 68 years), spinal fractures occurred in six of 40 patients receiving unfractionated heparin (10,000 units subcutaneously twice daily) compared with only one of 39 patients receiving LMWH (103) . In animal experiments and in a clinical trial of pregnant patients (102) , there is evidence that the heparin-induced osteopenia persists for an extended period after heparin is stopped when compared with LMWH. The actual cause of the osteoporosis is still uncertain (15) . This complication is a concern particularly with the use of unfractionated heparin in elderly postmenopausal patients. Evidence from animal experiments (104, 105) and from clinical trials (101, 102) indicate that the risk of heparin-induced osteoporosis is lower with the LMWH than with unfractionated heparin and data of clini-cally evident osteoporosis have been comparable with the use of long-term LMWH when compared with warfarin.
Other Practical Issues Related to the Use of the Heparins
One advantage of the use of unfractionated heparin is that the antithrombotic activity can be reversed with protamine sulphate (15) . The response to protamine sulphate varies with the different LMWH preparations. In a recent article it was shown that the response to protamine sulphate differed with the reducing amounts of sulphate on the side chains of the LMWH molecules (106) . Suppression of factor Xa activity varied between 51.4% and 85.7%, with the highest neutralization being with tinzaparin (85.7%) and dalteparin (74.0%) (106) .
In patients taking pressor agents or critically ill patients in the intensive care unit subcutaneous administration of LMWH may yield inadequate blood levels as measured by factor Xa levels, and in such patients intravenous administration of the heparins may be efficacious (107) .
CONCLUSION
Venous thromboembolism is a common problem in the elderly population with age being a significant risk factor. The treatment of venous thromboembolism in the elderly population presents certain unique problems related to aging, which includes numerous comorbid conditions, decreasing body weight, and increasing renal insufficiency. These conditions have been particularly problematic with the use of warfarin but increasing age has also been demonstrated to be a risk factor for bleeding in patients taking unfractionated heparin. LMWHs are efficacious and safe for the treatment of venous thromboembolism in a large number of clinical trials involving a number of patients in the older age brackets. These preparations do differ in their chemical and pharmacological properties and in their clearance in patients with renal insufficiency, so familiarity with the individual products is necessary to avoid complications such as accumulation of the drug. From clinical trials and numerous cohort studies it is shown that LMWH can be safely used for the treatment of venous thromboembolism in both the hospital and the out-of-hospital setting, which is particularly appropriate for a large number of elderly patients. 
